title: Using gross national product to calculate acceptable immunisation costs: deploying cost-effectiveness calculations in reverse.
authors.affiliation: Department of Pediatrics and Neonatology, St Stephen's Hospital, Tis Hazari, Delhi, India.
authors.forename: Vineet
authors.initials: V
authors.lastname: Tyagi
authors.forename: Saroj K
authors.initials: SK
authors.lastname: Singh
authors.forename: Ashu
authors.initials: A
authors.lastname: Sawhney
authors.forename: Vikas
authors.initials: V
authors.lastname: Taneja
authors.forename: Jacob M
authors.initials: JM
authors.lastname: Puliyel
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D003362:Cost-Benefit Analysis; D017048:Health Care Costs; D006509:Hepatitis B / Q000150:complications / Q000191:economics* / Q000517:prevention & control; D017325:Hepatitis B Vaccines / Q000191:economics*; D006801:Humans; D017589:Immunization Programs / Q000191:economics*; D007194:India / Q000453:epidemiology; D014611:Vaccination / Q000191:economics*
chemical_list: D017325:Hepatitis B Vaccines